Search

everythinglearnresearchcommunity

for

Search:↓

PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

Topical dutasteride is more effective than oral finasteride for male pattern hair loss, with fewer side effects. Some prefer oral treatments for convenience, while others use topical solutions like minoxidil and dutasteride, sometimes with microneedling, for better results.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

David Dobrik uses Minoxidil and possibly Finasteride for hair loss but applies them incorrectly. Users suggest he consider surgery due to his financial capability.

PP405 is being discussed for hair regrowth, with mixed opinions on its effectiveness and legitimacy. Some users report early signs of regrowth, while others are skeptical about its authenticity and results.

PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.

Some users maintained hair gains after stopping microneedling while continuing minoxidil and finasteride, while others saw no improvement or experienced hair breakage. One user switched to oral minoxidil and continued finasteride and dutasteride after seeing no results from microneedling.

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.

Chlorine dioxide was discussed as a potential hair growth treatment, with a method involving spraying it on the scalp and covering it with a cap. Concerns were raised about its safety, comparing it to bleach.

Increasing the dutasteride dose to 2.5 mg may significantly reduce DHT and promote hair regrowth, with similar side effects to lower doses. Some users combine dutasteride with minoxidil and finasteride for better results, but there are concerns about long-term effectiveness and availability.

A user shared a 9-month update on hair loss treatment, reporting positive results from taking 1 mg of finasteride and 1.25 mg of minoxidil daily. The discussion includes varied experiences with these treatments, questions about side effects, and comments on the unpredictability of treatment effectiveness.

A user shared their frustration about their cousin's refusal to take their advice on using finasteride for aggressive hair loss, despite the cousin's desperation and current use of minoxidil and consideration of PRP injections. The user, who has done extensive research, suggested the cousin needs a 5ar inhibitor, but the cousin dismisses the advice because the user isn't a doctor.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.

The user has maintained their hairline with finasteride for 5 years and saw no results from minoxidil. They are inquiring if tretinoin alone can cause hair regrowth.

SCUBE3 clinical trials for hair loss treatment to start this year. Treatment may involve regular, painless scalp injections to maintain hair growth.

Ordering Pyrilutamide from Minoxidilmax to use as an experimental topical treatment for hair loss, with discussion of the carrier used in trials and encouragement from other users.

Actifollic selling Pyrilutamide as a treatment for hair loss, with people debating its efficacy compared to Minoxidil and Finasteride in combination with RU58841.

A user's 2.5 year transformation of using 0.5mg finasteride and RU58841 to combat hair loss, with the possibility of increasing the RU for further regrowth.

Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

CB 03 01 (Breezula) was tried for hair loss but showed no significant improvement, with issues in dissolving and application. Finasteride and dutasteride remain the most effective treatments, while minoxidil is also used; CB's effectiveness is questioned, and topical alternatives like bicalutamide are considered.

Minoxidil and finasteride are the main treatments for hair loss, with Breezula and hair cloning being explored. No definitive cure is available yet.

A user is seeking hair loss treatments without using systemic DHT blockers like finasteride due to side effects. Suggestions include clascoterone (not FDA approved), pyrilutamide, RU58841, and low-dose topical finasteride, with a recommendation to consult a doctor.

The user has been using oral finasteride and topical minoxidil for years without success and is seeking alternative treatments. Suggestions include switching to oral minoxidil, adding dutasteride, trying topical treatments, or considering microneedling.

The conversation discusses using foam minoxidil with tretinoin cream for hair loss, with users sharing experiences on tretinoin strengths of 0.025% and 0.05%. Some users report irritation with higher tretinoin concentrations and note that foam minoxidil may be less effective than liquid.

A 22-year-old male has been using Dutasteride 0.5 mg every other day and Minoxidil 5% daily since December 2024 for hair loss, with no side effects reported. Users discuss varying dosages of Dutasteride, with some expressing concerns about higher doses.

The conversation discusses the effectiveness and skepticism around topical dutasteride for hair loss, with mentions of combining it with other treatments like minoxidil and oral medications. Some users doubt its efficacy due to lack of independent studies and potential conflicts of interest.

A user reported better hair regrowth with 5 mg oral minoxidil and 1 mg dutasteride than with finasteride and topical minoxidil, calling topical minoxidil a scam. Replies varied, with some defending topical minoxidil, questioning the user's application method, and suggesting that previous treatments might be contributing to the observed results.

A 42-year-old man is using topical finasteride, oral minoxidil, microneedling, ketoconazole shampoo, and various oils for hair loss treatment and is happy with the improvements after 5 months. He experienced mild side effects from finasteride, including temporary testicular pain and changes in libido, but no side effects from minoxidil.